bioMerieux (OTCMKTS:BMXMF) Receives Consensus Rating of “Reduce” from Analysts

Shares of bioMerieux (OTCMKTS:BMXMF) have earned an average recommendation of “Reduce” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a hold rating to the company.

BMXMF has been the subject of a number of analyst reports. Zacks Research upgraded bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. UBS Group lowered bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Piper Sandler started coverage on shares of bioMerieux in a research report on Thursday, June 11th. They issued a “neutral” rating for the company. Finally, Morgan Stanley lowered shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd.

bioMerieux Price Performance

Shares of BMXMF stock opened at $80.66 on Friday. bioMerieux has a 12-month low of $77.00 and a 12-month high of $152.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48. The business has a 50 day simple moving average of $81.83 and a 200 day simple moving average of $101.48.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.